Maria Bermudez, MD
Internal Medicine · Danville, PANPI 1851558118
Payments from drug & device makers
Across 33 payments — averaging $195.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cormedix Inc.$3K
- Nxstage Medical, Inc.$2K
- Baxter Healthcare$1K
- Fresenius USA Marketing, Inc.$109
- Vantive US Healthcare LLC$73
- Calliditas Therapeutics US Inc.$39
- plus $56 from 2 others
What the payments were for
- Consulting fees$3,27251%
- Travel & lodging$1,99331%
- Food & beverage$1,19719%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cormedix Inc. | 1 | $3,000 |
| Nxstage Medical, Inc. | 17 | $1,739 |
| Baxter Healthcare | 10 | $1,447 |
| Fresenius USA Marketing, Inc. | 1 | $109 |
| Vantive US Healthcare LLC | 1 | $73 |
| Calliditas Therapeutics US Inc. | 1 | $39 |
| Novartis | 1 | $33 |
| Sanofi | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DefenCath$3,000
- NXSTAGE SYSTEM ONE$1,540
- Non-Franchise (NOF) - NonProduct$1,169
- NXSTAGE PUREFLOW SOLUTION$109
How this compares
$6,462 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuryxiaFerric Citrate | 16 | $20,424 |
| Calcium Acetate | 58 | $1,857 |
| Torsemide | 33 | $918 |
| Sevelamer Carbonate | 12 | $697 |
| Midodrine Hcl | 23 | $663 |
| Carvedilol | 17 | $264 |
| Amlodipine Besylate | 28 | $213 |
| Omeprazole | 19 | $205 |
| Lactulose | 13 | $198 |
| Atorvastatin Calcium | 12 | $112 |
| Famotidine | 12 | $106 |
| Losartan Potassium | 17 | $72 |
| Furosemide | 12 | $39 |
| Ondansetron Hcl | 11 | $33 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Danville
- Christopher StillDanville$7.1M
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.